Q-omics provides the consensus-scored NT5DC4 profile across patient tissues and cancer cell-line models. NT5DC4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NT5DC4 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NT5DC4 RNA expression shows 13,977 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where NT5DC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5DC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5DC4 survival associations across molecular data types. NT5DC4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5DC4 RNA expression–survival associations across cancer types. High NT5DC4 expression shows unfavorable associations in KIRC, ACC, UVM and LGG, but favorable associations in BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NT5DC4 RNA expression.
This table summarizes NT5DC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NT5DC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5DC4 shows higher tumor expression in HNSC, BLCA, COAD, LUAD, KICH and STAD. The HNSC box plot shows higher NT5DC4 RNA expression in tumor versus normal tissue (log2 FC = +0.406, t-test p < 0.001).
This table shows molecular features associated with NT5DC4 in patient tissues and cancer cell lines. In patient samples, NT5DC4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5DC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
